Market capitalization | $40.49m |
Enterprise Value | $451.36m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.36 |
P/S ratio (TTM) P/S ratio | 0.39 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -33.81% |
Revenue (TTM) Revenue | $103.46m |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
4 Analysts have issued a Agenus Inc. forecast:
4 Analysts have issued a Agenus Inc. forecast:
Dec '24 |
+/-
%
|
||
Revenue | 103 103 |
34%
34%
|
|
Gross Profit | 90 90 |
36%
36%
|
|
EBITDA | -111 -111 |
24%
24%
|
EBIT (Operating Income) EBIT | -124 -124 |
22%
22%
|
Net Profit | -227 -227 |
8%
8%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
Head office | United States |
CEO | Garo Armen |
Employees | 316 |
Founded | 1994 |
Website | www.agenusbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.